ELCC 2017

1:33
Exciting current topics in lung cancer
Solange Peters
1:13
Phase II study of Durvalumab for patients with NSCLC
David Gandara
1:48
Evolving guidelines for molecular testing in lung cancer
Fred Hirsch
0:51
Current treatment landscape for neuroendocrine tumors
Keith Kerr
2:04
Biomarker testing in NSCLC
Keith Kerr
1:29
The LUME-BioNIS study and its aims
Keith Kerr
1:10
The BIRCH trial data discussed by Dr Peters
Solange Peters
2:29
The open questions surrounding immunotherapy and targeted therapy in lung cancer
Solange Peters
1:46
Challenges and opportunities for patients with advanced NSCLC
Solange Peters
2:43
Increasing patient access to the latest treatments
Solange Peters
0:47
Why is European Lung Cancer Conference so important?
Solange Peters
1:15
Molecular tools for lung cancer therapies
Charles Swanton
2:09
Benefits of targeted therapeutics in Lung Cancer
David Carbone
2:07
Increasing treatment options for NSCLC
David Gandara
1:52
ESMO guidelines for thymic cancer management
Nicolas Girard
2:09
Genetic evolution of NSCLC
Charles Swanton
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals